ME/CFS Science @mecfsscience.org · 14/07/20264) There were a couple of Long Covid studies that reported increased HERV-W ENV in Long Covid patients. This trial therefore used this as an inclusion criterion in their trial. It focused only on LC patients who were positive for HERV-W ENV in their blood. 150
ME/CFS Science @mecfsscience.org · 14/07/20265) This was a large placebo-controlled and international trial: it recruited 203 patients from three European countries (Switzerland, Italy, and Spain) involving 14 centers. The primary outcome was the PROMIS Fatigue SF 7a scale. 150
ME/CFS Science @mecfsscience.org · 14/07/20266) The main result is shown in the figure below. Temelimab had no effect on fatigue, and the same null results were seen for the secondary outcomes, including several cognitive tests and biomarkers. 160